rs1801020 — F12 46C>T

Factor XII and the Contact Coagulation Paradox

Coagulation Factor XII (FXII), also called Hageman factor, is the initiating enzyme of the contact activation pathway¹¹ contact activation pathway
The intrinsic coagulation pathway, triggered when blood contacts negatively charged surfaces such as glass, collagen, or bacterial polyphosphates of coagulation. When activated, FXII sets off a cascade that ultimately generates thrombin and produces a fibrin clot. FXII also activates the kallikrein-kinin system, generating bradykinin — a potent vasodilator implicated in inflammation and angioedema. The rs1801020 variant (known as 46C>T in papers, using the coding-strand notation of the minus-strand F12 gene) is the single most important common genetic determinant of circulating FXII levels, reducing protein production through a translational mechanism rather than a structural change.

The Mechanism

The F12 gene resides on chromosome 5q35.3 and is transcribed on the minus strand. The rs1801020 polymorphism sits in the 5' untranslated region (5'UTR)²² 5' untranslated region (5'UTR)
The region of mRNA upstream of the protein-coding sequence; changes here affect translation efficiency without changing the protein sequence itself of F12, four nucleotides upstream of the normal start codon. The T allele (A on the plus strand) creates a new upstream ATG start codon that is read by ribosomes first, producing a short 2-amino-acid peptide that prevents the ribosome from reaching the authentic start site. This reduces translation of the full-length FXII protein. The effect is dose-dependent: CC carriers produce ~129% of average FXII; CT heterozygotes ~92%; TT homozygotes ~56%³³ CC carriers produce ~129% of average FXII; CT heterozygotes ~92%; TT homozygotes ~56%
Calafell et al. Human Molecular Genetics 2010.

Bayesian quantitative trait nucleotide analysis⁴⁴ Bayesian quantitative trait nucleotide analysis
A statistical method for identifying causal variants within a quantitative trait locus across 26 polymorphisms in the F12 locus confirmed that rs1801020 alone accounts for essentially all the heritable variation in plasma FXII levels, making it an unusually clean example of a single common variant with a large, well-defined biochemical effect.

The Evidence

The relationship between lower FXII levels and disease risk is paradoxical and evidence is mixed. Animal studies and human data converge on a surprising picture: low FXII appears protective against thrombosis, not harmful⁵⁵ protective against thrombosis, not harmful
FXII-deficient mice are protected from pathological clotting without increased bleeding risk.

A meta-analysis of 16 candidate-gene studies (4,386 cases, 40,089 controls)⁶⁶ meta-analysis of 16 candidate-gene studies (4,386 cases, 40,089 controls)
Johnson et al. Am J Epidemiology 2011 found only a borderline association with myocardial infarction for the dominant model (OR 1.13, 95% CI 1.00–1.27) and no significant association with venous thromboembolism, leading the authors to conclude the overall evidence is weak.

However, a Spanish case-control study of 250 venous thrombosis patients found that TT homozygotes had an adjusted OR of 4.82 (95% CI 1.5–15.6)⁷⁷ adjusted OR of 4.82 (95% CI 1.5–15.6)
Tirado et al. Thrombosis and Haemostasis 2004 for VTE — a striking finding replicated in some but not all subsequent cohorts. The WOSCOPS study (441 CHD cases, 990 controls)⁸⁸ WOSCOPS study (441 CHD cases, 990 controls)
Zito et al. Atherosclerosis 2002 found TT genotype to be an independent CHD risk factor (OR 1.48, 95% CI 1.01–2.17), particularly in pravastatin-treated subjects.

Separately, higher FXII protein levels — the opposite of what T allele carriers have — were associated with increased hemorrhagic stroke risk (HR 1.51 per SD, p<0.05)⁹⁹ increased hemorrhagic stroke risk (HR 1.51 per SD, p<0.05)
Johansson et al. Cerebrovascular Diseases Extra 2017 in a northern Swedish prospective cohort, with no ischemic stroke association. This suggests FXII's role is complex: high levels may predispose to hemorrhagic vascular events while the effect of low levels on arterial thrombosis remains uncertain.

The Cardiovascular Health Study (n=5,411)¹⁰¹⁰ Cardiovascular Health Study (n=5,411)
Olson et al. J Thrombosis and Haemostasis 2015 confirmed that the T allele strongly lowers peak thrombin generation (β=−34.2 nM, p=3.3×10⁻²²) but found no association between rs1801020 genotype and incident ischemic stroke in a multi-cohort meta-analysis.

Practical Actions

For TT homozygotes (AA on the plus strand), FXII levels are approximately half of normal, substantially reducing contact pathway coagulation. While this does not cause clinical bleeding — Factor XII deficiency does not cause bleeding disorders even in severely deficient individuals¹¹¹¹ Factor XII deficiency does not cause bleeding disorders even in severely deficient individuals
unlike Factor VIII or IX deficiency — the cardiovascular implications warrant proactive monitoring. Some studies suggest elevated cardiovascular risk despite the anticoagulant effect, possibly mediated through reduced thrombolytic activity or kallikrein-kinin pathway dysregulation.

Heterozygotes (AG) have modestly reduced FXII (~92% of average) and a generally unremarkable risk profile, but may benefit from standard cardiovascular risk monitoring as part of routine care.

Interactions

The F12 gene interacts with prekallikrein (KLKB1, rs3733402) — both encode contact activation pathway enzymes that reciprocally activate each other. Carriers of reduced-function variants in both genes may experience synergistically lower contact pathway activity. The bradykinin arm of FXII activation also intersects with the renin-angiotensin system: rs1801020 and KLKB1 variants have been associated with reduced active renin formation. Compound carriers of rs1801020 TT and the KLKB1 rs3733402 low-activity genotype may warrant a combined evaluation of cardiovascular risk biomarkers.